Prescription Predicament: How Three New Models are Tackling Drug Prices

Huddle #Trends are monthly reports dissecting key healthcare trends that impact patients, physicians, and the system. Exclusive to Huddle+ members.

The Centers for Medicare and Medicaid Services revealed three experimental models to improve drug affordability and access. Each model is unique, targeting different areas within the drug market that contribute to high drug prices.

While these are experimental models, they have the potential to reshape the drug market and improve the patient experience. So, let’s talk about it.

In this article, I’ll briefly discuss the current state of drug prices in the U.S., dive into CMS’s three experimental models to lower drug prices, and discuss key players tackling drug prices.

Subscribe to Huddle+ to read the rest.